Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle

Anaplastic thyroid cancer (ATC) represents the type with the worst prognosis among thyroid cancers. In ATC with a highly invasive phenotype, selective targeting of TERT with BIBR1532 may be a goal-driven approach to preserving healthy tissues. In present study, it was aimed to investigate the effects of treatment of SW1736 cells with BIBR1532 on apoptosis, cell cycle progression, and migration. The apoptotic effect of BIBR1532 on SW1736 cells was examined using the Annexin V method, the cytostatic effect using cell cycle test, migration properties using wound healing assay. Gene expression differences were determined by real-time qRT-PCR and differences in protein level by ELISA test. BIBR1532-treated SW1736 cells had 3.1-fold increase in apoptosis compared to their untreated counterpart. There was 58.1% arrest in the G(0)/G(1) phase and 27.6% arrest in the S phase of the cell cycle in untreated group, treatment with BIBR1532 increased cell population in G(0)/G(1) phase to 80.9% and decreased in S phase to 7.1%. Treatment with the TERT inhibitor resulted in a 50.8% decrease in cell migration compared to the untreated group. After BIBR1532 treatment of SW1736 cells, upregulation of BAD, BAX, CASP8, CYCS, TNFSF10, CDKN2A genes, and downregulation of BCL2L11, XIAP, CCND2 genes were detected. BIBR1532 treatment resulted in an increase in BAX and p16 proteins, and a decrease in concentration of BCL-2 protein compared to untreated group. Targeting TERT with BIBR1532 as a mono drug or using of BIBR1532 at priming stage prior to chemotherapy treatment in ATC may present a novel and promising treatment strategy.

Automated summary

Treatment with BIBR1532 in ATC cells leads to increased apoptosis, cell cycle arrest, and decreased cell migration. This treatment upregulates the expression of BAD, BAX, CASP8, CYCS, TNFSF10, and CDKN2A genes, and downregulates the expression of BCL2L11, XIAP, and CCND2 genes. Additionally, BIBR1532 increases the expression of BAX and p16 proteins, while decreasing the concentration of BCL-2 protein. Therefore, targeting TERT with BIBR1532 as a mono drug or priming treatment before chemotherapy may offer a novel and promising therapeutic strategy for ATC.